Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$11.25
-0.04 (-0.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $145.8M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.7B
P/E
18.4x
↓EV/EBITDA
10.6x
↓ROE
14.0%
↑Gross Margin
69.8%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.4%
FCF CAGR
—
FCF margin
28.9%
FCF / Net income
1.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $812.3M · net income $195.1M · FCF $235.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $812.3M | $812.3M | $714.4M | $671.6M | $655.0M |
| Net Income | $195.1M | $195.1M | $200.7M | $162.9M | $161.6M |
| EBITDA | $322.4M | $322.4M | $325.1M | $267.4M | $235.3M |
| EPS | 0.61 | 0.61 | 0.61 | 0.50 | 0.49 |
| Gross Margin | 69.8% | 69.8% | 69.5% | 64.2% | 68.4% |
| Operating Margin | 22.8% | 22.8% | 19.8% | 20.4% | 20.8% |
| Net Margin | 24.0% | 24.0% | 28.1% | 24.3% | 24.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.18 | 0.37 | 0.39 |
| Current Ratio | 1.75 | 1.75 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $235.0M | $235.0M | $145.8M | $123.9M | $-86.9M |
| Returns | |||||
| ROE | 14.0% | 14.0% | 15.9% | 13.7% | 14.9% |
| Valuation | |||||
| P/E | 18.44 | 18.44 | 12.38 | 20.20 | 20.85 |
| EV/EBITDA | 10.59 | 10.59 | 7.82 | 12.86 | 15.22 |
| P/B | 2.59 | 2.59 | 1.97 | 2.76 | 3.10 |
| Growth & Yield | |||||
| Revenue Growth | 13.7% | 13.7% | 6.4% | 2.5% | — |
| EPS Growth | 0.0% | 0.0% | 22.0% | 2.0% | — |
| Dividend Yield | 2.2% | 2.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
17.8%
EPS terminal req.
$1.00
Spread vs growth
-17.8%
5Y implied EPS CAGR
14.6%
EPS terminal req.
$1.21
Spread vs growth
-14.6%
10Y implied EPS CAGR
12.3%
EPS terminal req.
$1.95
Spread vs growth
-12.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+25.0%
Start / end P/E
15.0x → 18.4x
EPS bridge
0.61 → 0.61
Residual
-0.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.